Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Key Points

• Entera Bio Ltd. saw a significant reduction in short interest, dropping by 33.0% in August from the previous month, bringing the total to 37,200 shares.
• The company's stock declined 4.6% to $2.06, with a market capitalization of approximately $94.06 million and a consensus rating of "Strong Buy" from analysts.
• Institutional investors have increased their stake in Entera Bio, with notable increases from Northern Trust Corp and Knoll Capital Management, highlighting growing institutional interest.

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a large drop in short interest in August. As of August 15th, there was short interest totaling 37,200 shares, adropof33.0% from the July 31st total of 55,500 shares. Based on an average daily volume of 118,100 shares, the short-interest ratio is currently 0.3 days. Based on an average daily volume of 118,100 shares, the short-interest ratio is currently 0.3 days.

Entera Bio Stock Down 4.6%

ENTX stock traded down $0.10 during midday trading on Friday, reaching $2.06. The company had a trading volume of 210,792 shares, compared to its average volume of 55,477. The stock has a 50 day moving average price of $1.94 and a 200 day moving average price of $1.95. The firm has a market capitalization of $94.06 million, a PE ratio of -7.92 and a beta of 1.69. Entera Bio has a fifty-two week low of $1.50 and a fifty-two week high of $2.79.

Entera Bio (NASDAQ:ENTX - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.05. Entera Bio had a negative return on equity of 77.75% and a negative net margin of 4,525.11%. Research analysts predict that Entera Bio will post -0.28 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised Entera Bio to a "strong-buy" rating in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Strong Buy" and an average target price of $10.00.

Hedge Funds Weigh In On Entera Bio

A number of hedge funds have recently modified their holdings of ENTX. Northern Trust Corp bought a new stake in Entera Bio during the fourth quarter valued at about $450,000. Knoll Capital Management LLC boosted its holdings in Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after acquiring an additional 2,000,000 shares during the period. HighTower Advisors LLC boosted its holdings in Entera Bio by 53.3% during the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock valued at $31,000 after acquiring an additional 6,310 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in Entera Bio by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock valued at $747,000 after acquiring an additional 25,900 shares during the period. Finally, Bessemer Group Inc. bought a new stake in Entera Bio during the second quarter valued at about $268,000. 14.11% of the stock is owned by institutional investors and hedge funds.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.